[Skip to Content]
[Skip to Content Landing]
Citations 0
April 5, 2006

Efficacy and Safety of Edifoligide

JAMA. 2006;295(13):1513-1515. doi:10.1001/jama.295.13.1513-b

To the Editor: In the PREVENT IV study,1 edifoligide did not affect the rate of VGF, and on the basis of angiographic data the PREVENT IV investigators concluded that edifoligide did not have an appreciable effect on neointimal hyperplasia. We believe it may be premature to conclude that the lack of clinical benefit is due to a failure to inhibit neointimal proliferation and suggest 3 alternative explanations.

First Page Preview View Large
First page PDF preview
First page PDF preview